Innovation Report on Imaging-Based FFR Industry Released: VB Roundtable Episode 3 to Discuss Value and Challenges of Imaging FFR

On January 15, 2020, DeepPulse Score® obtained the first Class III medical device registration certificate for artificial intelligence issued by the National Medical Products Administration (NMPA), gaining approval for clinical application. This milestone marked the beginning of the commercialization of domestically produced imaging-based FFR products in China.

So, what development stage is China's imaging-based FFR industry in? What is its market potential? Who are the representative companies and what are their business models? To clarify these questions, VCBeat conducted researchOver 10 Imaging FFR Companies, analyzed2,000+ Industry Data Reports, authored"Imaging FFR Industry Innovation Report", aiming to provide a comprehensive analysis of the imaging FFR industry from multiple dimensions—including policy, technology, market, capital, and typical case studies—with the goal of offering industry participants relatively comprehensive information on the imaging FFR sector.

The report authors indicate that the state is actively encouraging the market launch and clinical adoption of imaging-based FFR products, which will significantly increase the prevalence of FFR testing.It is expected that within two years after 2020, 3 to 5 companies will obtain Class III registration certificates from the National Medical Products Administration (NMPA) for their imaging-based FFR products.

The business models of imaging FFR companies can be categorized intoIn-Hospital Independent Model, In-Hospital Collaborative ModelandThird-Party Imaging FFR Testing Center Model, different business models entail varying relationships among market participants.

Currently, the domestic imaging-based FFR market in China is still in its early stages, with most companies yet to achieve profitability and product penetration remaining low. However, driven by technological innovation, policy improvements, and market demand, the imaging-based FFR market holds strong growth potential.The market size is expected to reach 1.5 billion yuan in 2025, innovations in service models and the involvement of insurance will further expand the market space.

From a financing perspective, domestic capital began entering the image-based FFR industry in 2016.Over the past four years, a total of nine companies have completed 19 rounds of financing.Overall, the investment and financing landscape for the image-based FFR industry remains in its early stages, with a limited number of funding rounds; 71% of these rounds are concentrated at Series A or earlier. This presents favorable financing prospects for companies in the image-based FFR sector. To capitalize on this opportunity, these enterprises should accelerate innovation in technology and services, building market competitiveness through high-quality products and differentiated service models to attract capital interest.

Thus, from the perspectives of industry academics, enterprises, and investors

What are the advantages of imaging-based FFR compared to traditional FFR?

How to Increase the Utilization Rate of FFR?

What Is the Value of the Large-Scale Clinical Trial FAVOR III China, and What Is Its Significance for the Widespread Adoption of Imaging-Based FFR?

What Are the Current Potential Business Models and Challenges in the Field of Imaging-Based FFR?

How Did HeartFlow, the Industry Benchmark, Evolve into an Industry Unicorn?

Thoughts and Logic on Investing in the Imaging FFR Sector?

……

Tonight19:30(Thursday, March 5), VCBeat was also honored to inviteProfessor, School of Biomedical Engineering, Shanghai Jiao Tong UniversityTu Shengxian、Xiang Jianping, Founder and CEO of MaiFlow TechnologyandLi Zhenming, Partner at Boxing Capital, attended and participated in the event to jointly discuss key topics such as the business model, value trends, and investment logic of imaging-based FFR.

Clickhttp://shareonline.vcbeat.top/watch/5011638, enter the live broadcast room or scan the QR code to join the discussion group to receive the report and access more information.

Subject:The Value and Challenges of Imaging-Based FFR

Time:March 5, 2020 (Thursday) 19:30–21:00

Host:

Wang Xiaohang, Director of VCBeat, Author of the "Industry Innovation Report on Imaging FFR"

Guest:

Tu Shengxian, Professor at the School of Biomedical Engineering, Shanghai Jiao Tong University, and Fellow of the American College of Cardiology (FACC)

Xiang Jianping, Founder and CEO of PulseFlow Technology, the company develops a non-invasive functional assessment system for cardiovascular diseases.

Li Zhenming, Partner at Boxing Capital, has led investments in over 20 healthcare companies and has focused on the cardiovascular field for many years.

Live Stream Link:http://shareonline.vcbeat.top/watch/5011638